Prometheus Biosciences Inc.
- Address
- 3050 Science Park Road
Sponsor Overview
Specializations
Crohn’s disease
Prometheus Biosciences Inc. is active in inflammatory bowel disease research with a focus on Crohn’s disease, including clinical programs examining symptom control, endoscopic improvement, and clinical remission outcomes.
- Inflammatory bowel disease
- Crohn’s disease
- Endoscopic response
- Clinical remission
The sponsor’s work in this area reflects a therapeutic interest in disease activity reduction and intestinal healing.
Ulcerative colitis
The company also funds research in ulcerative colitis, with attention to induction therapy, tolerability, and the achievement of remission in patients with active colonic inflammation.
- Ulcerative colitis
- Induction therapy
- Safety and tolerability
- Remission
Its clinical activity in this field centers on therapies for chronic inflammatory disease of the colon.
Systemic sclerosis associated with interstitial lung disease
Prometheus Biosciences Inc. is involved in studies of systemic sclerosis associated with interstitial lung disease, a complex autoimmune condition marked by fibrotic lung involvement and declining respiratory function.
- Systemic sclerosis
- Interstitial lung disease
- Autoimmune disease
- Pulmonary fibrosis
Research in this area reflects interest in preserving forced vital capacity and addressing organ-threatening manifestations of connective tissue disease.
Immune-mediated disease
The sponsor’s trial portfolio is concentrated in immune-mediated inflammatory disorders, with overlapping interest in gastrointestinal and rheumatologic disease domains.
- Immune-mediated inflammation
- Gastrointestinal disease
- Rheumatologic disease
- Fibrotic disease
This therapeutic scope spans chronic conditions where immune dysregulation drives tissue injury and progressive clinical burden.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Safety, Efficacy, and Pharmacokinetics of PRA023 Induction Therapy in Moderate to Severe Ulcerative Colitis: A Phase 2, Double-Blind, Placebo-Controlled Study |  Czechia France Hungary Poland | Not Recruiting |
| Evaluation of Safety, Efficacy, and Pharmacokinetics of Tulisokibart in Patients with Moderately to Severely Active Crohn's Disease: A Phase 2a, Open-Label Study | Czechia France Poland | Not Recruiting |
| Tulisokibart in Systemic Sclerosis-Associated Interstitial Lung Disease: A Randomized, Placebo-Controlled Trial of Safety and Efficacy |  Belgium France Germany Hungary Italy Poland Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 50 sites across their trial portfolio.
Therapeutic Focus
- 1.Digestive System Diseases2 trials280 other sponsors
- 2.Immune System Diseases1 trial322 other sponsors
Partnered Research Centres
50 centres- Address
- Ul. Aleje Raclawickie 23, 20-049 Lublin
- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Largo Giovanni Alessandro Brambilla 3, 50134 Florence
- Address
- Via Giovanni Amendola 2, 42122 Reggio Emilia
- Address
- Semmelweis Utca 1, 5700 Gyula
- Address
- Ul. Kosynierow Gdynskich 61, 93-357 Lodz
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Prometheus Biosciences Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.